Table of contents
- Trial overview
- Study design and treatment groups
- Who can participate
- What is being measured
- Trial status and size
Trial overview
One authorised Phase 3 trial is studying LIGUFALIMAB in people with recurrent and/or metastatic squamous cell carcinoma of the head and neck.[1] This is an interventional study, which means the researchers give study treatment and then measure the results.[1]
Study design and treatment groups
The trial compares ivonescimab plus LIGUFALIMAB with pembrolizumab, and also compares ivonescimab alone with pembrolizumab.[1] The study summary says this is for first-line treatment, meaning the first treatment given for this cancer.[1]
The trial includes a treatment group with LIGUFALIMAB given as an intravenous infusion, which means it is given through a vein.[1] The source also lists pembrolizumab and ivonescimab as the other study treatments.[1]
Who can participate
The study is aimed at patients with recurrent and/or metastatic head and neck squamous cell carcinoma.[1] The brief summary also says the population is PD-L1 positive with CPS 1 or higher.[1] PD-L1 positive means the tumor has a marker that can help guide treatment choice, and CPS is a score used to measure that marker.[1]
What is being measured
The main outcome is overall survival.[1] Overall survival means how long patients live after starting treatment, and it is a key way to see whether a cancer treatment helps people live longer.[1]
Trial status and size
The trial status is Authorised.[1] The planned enrollment is 700 participants, showing that this is a large study.[1]
